The HCPLive Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.
April 25th 2024
A retrospective study challenges preoperative withholding of GLP-1 RAs in diabetes patients undergoing surgery, citing no increased risk of postoperative respiratory complications.
Addressing Healthcare Inequities: Tailoring Management Plans to Address Healthcare Disparities in Cystic Fibrosis
View More
Revolutionizing Early-Stage NSCLC Treatment: Pathologists’ Key Insights into Predicting Pathologic Responses to Immunotherapies
View More
Community Practice Connections™: 20th Annual Winter Lung Conference
View More
Medical Crossfire®: Key Strategies to Prioritize Testing and the Evolving Role of Genomic Alterations in Providing Precision NSCLC Care
View More
Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse
View More
Go To PER in Chicago
May 31, 2024 - June 2, 2024
Register Now!
The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward
View More
Respiratory Syncytial Virus: Understanding the Infection Burden and Anticipating the Impact of Vaccines
View More
Engaging the Multidisciplinary Care Team to Optimize Care of Patients With EGFR Mutation–Positive NSCLC: A Lung Cancer Tumor Board
View More
Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target
View More
25th Annual International Lung Cancer Congress®
July 25-27, 2024
Register Now!
24th Annual International Lung Cancer Congress®
View More
Engaging the Multidisciplinary Care Team to Optimize Care of Patients With EGFR Mutation-Positive NSCLC: A Lung Cancer Tumor Board
View More
Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC
View More
Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?
View More
Advances In™: Aligning Pathology and Oncology Efforts in the Community to Improve NSCLC Care
View More
Community Practice Connections: 7th Annual School of Nursing Oncology™
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC
View More
6th Annual Advanced Practice Collaborative
View More
Community Practice Connections™: 24th Annual International Lung Cancer Congress®
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
19th Annual New York Lung Cancers Symposium®
November 16, 2024
Register Now!
Let’s Get “Real”: Alpha-1 Antitrypsin Deficiency—Case-Based Perspectives on Managing Associated Emphysema
View More
Shaping the Management of COPD with Biologic Therapy
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
EGPA: Highlighting the Patient Journey to Improve the Differential Diagnosis and Accelerate the Initiation of Guideline-Based Care
View More
Identifying Actionable Biomarkers in NSCLC: Real World Case Discussions on Applications of Testing in the Treatment Planning Process
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Lung Cancer Tumor Board®: Enhancing Multidisciplinary Communication to Optimize Immunotherapy in Stage I-III NSCLC
View More
When Prophylaxis Is Contraindicated, Inferior Vena Cava Filter Can Benefit VTE
October 22nd 2013Mechanical prophylaxis for pulmonary embolism (PE) in the form of an inferior vena cava filter (IVCF) is an option for surgical patients who can't undergo chemical venous thromboembolism (VTE) prophylaxis.
Over-the-Counter Probiotics Can Lower Acute Upper Respiratory Tract Infection Risk
October 1st 2013A systematic review of 14 randomized controlled trials found a probiotic Lactobacillus strain taken daily lowers the risk of acute upper respiratory tract infection (URTI) without increasing the risk of adverse events.
Inadequate Vitamin D May Increase Risk of Certain Rheumatic Diseases
While substantial evidence already shows several genetic and environmental elements factor into immune-mediated rheumatic disease susceptibility, a recent review of hospital admissions data suggests vitamin D deficiency can single-handedly elevate a patient's risk of developing certain chronic conditions within that group of disorders.
Hospital Performance Rankings Don't Capture Cancer Operation Complexity
Although many US hospitals tout quality improvement in surgical outcomes, new research findings released at the national conference of the American College of Surgeons (ACS) National Surgical Quality Improvement Program (NSQIP) show that taking cancer operation performance into account would deliver a more accurate hospital rating.
Hyponatremia Increases Pneumonia Severity in Hospitalized Children
Although previous studies have already established that low serum sodium levels commonly occur in critically ill children who require hospitalization, a team of Polish researchers aimed to more closely evaluate the link between hyponatremia and the severity of a child's community-acquired pneumonia (CAP).
Hospitals Receive New Checklists in 10 Patient Safety Areas
The federal government's Partnership for Patients Hospital Engagement Networks (HENs), which work to improve patient care through implementation and dissemination of best practices in clinical quality, have released checklists for 10 areas of patient care.
Researchers Test Correlation between IBS Symptoms and Methane, Hydrogen Gas Concentrations
Researchers at the Hanyang University College of Medicine set the record straight on the association between IBS symptoms and methane and hydrogen gas produced by intestinal fermentation of lactulose and excreted in the breath during lactulose breath test.
High Rates of In-Hospital Cardiac Arrest Likely to Correlate with Poor Survival
Recent research from the University of Michigan Health Systems published in JAMA Internal Medicine found that hospitals with the highest rates of cardiac arrests are more likely to have the poorest survival rates for those cases.
FDA Expands Vibativ Approval to Combat Hospital-Acquired Pneumonia
Citing a need for new therapies to remedy serious diseases acquired in hospitals, the US Food and Drug Administration has expanded approval of Vibativ (telavancin) to treat bacterial pneumonia when alternative drugs aren't appropriate.
Promising Heart Failure Drug Receives ‘Breakthrough' FDA Designation
The US Food and Drug Administration has awarded "breakthrough therapy" status to a synthetic copy of a naturally occurring human hormone for the treatment of acute heart failure (AHF), drug developer Novartis announced today.
FDA Limits Usage, Duration of Hyponatremia Drug Due to Observed Liver Damage Risk
Citing an increased risk of liver injury observed in recent clinical trials, the US Food and Drug Administration (FDA) has limited Samsca (tolvaptan) treatment to 30 days and recommended the oral selective vasopressin V2-receptor antagonist be discontinued in patients with signs of liver disease or symptoms of liver injury.
New Diabetes Management Guidelines Consider Concurrent Conditions
In diagnosing a patient with type 2 diabetes, an endocrinologist or primary care physician may struggle with developing healthy treatment targets when comorbid conditions like obesity and hypoglycemia are at play.
Omega-3 Therapy Vascepa Reduces Triglycerides in Severe Hypertriglyceridemia Patients
As an adjunct to diet and exercise, Amarin's lipid-regulating agent Vascepa (icosapent ethyl capsules) is indicated to reduce triglyceride levels in adult patients with severe hypertriglyceridemia, or very high triglyceride (TG) levels greater than or equal to 500 milligrams per deciliter (mg/dL).
Blood Thinner Brilinta Treats Acute Coronary Syndrome
Approved by the FDA in July 2011, AstraZeneca's Brilinta (ticagrelor tablets) is a twice-daily treatment to reduce the rate of myocardial infarction and cardiovascular death in adult patients with acute coronary syndrome.
New Injectable Gel May Prevent Heart Failure After Myocardial Infarction
Bioengineers at the University of California, San Diego have deemed a new injectable hydrogel safe and effective for repairing tissue damage caused by myocardial infarction, providing a platform to bring the gel to clinical trials within the next year.
Psychiatrist Proposes New Subspecialty to Treat Patients With Depression and Heart Disease
After finding abnormal elevations of cardiac inflammation in patients with depressive illness (DI), a psychiatrist at Loyola University Medical Center, in Maywood, Ill., has proposed a new subspecialty to diagnose and treat patients with both depression and cardiovascular disease (CVD).
Obstructive Sleep Apnea Not Associated With Hypertension in Community Cohort (AJRCCM)
February 1st 2012Research on people recruited randomly from the community suggests that, after adjusting for various demographic, behavioral, and physical characteristics, there is no association between sleep apnea and hypertension.
FDA Approves Drug for Rare Form of Cystic Fibrosis
January 31st 2012The FDA announced today that it had approved Kalydeco (ivacaftor) to treat cystic fibrosis caused by a rare genetic mutation. The drug was approved in just three months under the agency's priority review program and was developed by its manufacturer, Vertex Pharmaceuticals Inc., with assistance from the Cystic Fibrosis Foundation.